Clinical-stage biotech company Anbogen announced on Friday that it has entered into a collaboration with BeiGene (Nasdaq:BGNE)(SEHK:6160)(SSE:688235), a pharmaceutical company, to evaluate the combination of Anbogen's HDAC inhibitor, ABT-301, and BeiGene's anti-PD-1 antibody, tislelizumab, in a global Phase II trial targeting mismatch repair–proficient (pMMR) or microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
Over 95% of mCRC patients, whose tumours are pMMR/MSS, do not benefit from current immune checkpoint inhibitors (ICIs), highlighting a critical unmet need. ABT-301, a novel HDAC inhibitor, has demonstrated a favourable safety profile and potential to enhance ICI effectiveness by modulating the immune response in preclinical studies.
The upcoming trial will assess the safety, tolerability, and preliminary efficacy of the ABT-301 and tislelizumab combination, with and without Bevacizumab, in these patients. BeiGene will supply tislelizumab for this study.
Enrollment is slated to begin in Q1 2025 at multiple centres.
Hemogenyx Pharmaceuticals schedules Phase i clinical trial for HEMO-CAR-T
SciBase and Kilabs partner to advance skin cancer diagnostics in Italy
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
I-Mab announces presentation of Phase 1 dose data for givastomig at SITC 2024
Biond Biologics signs clinical trial collaboration and supply agreement with Merck KGaA
Foresee Pharmaceuticals submits US FDA New Drug Application for three-month version of CAMCEVI
GlycoMimetics to combine with Crescent Biopharma
MilliporeSigma expands ADC manufacturing capacity
Merck and Moderna launch new Phase 3 trial for cancer vaccine
RaySearch Laboratories AB names new CFO
Genprex partners with University of Michigan to explore Reqorsa for lung cancer treatment
Elicera Therapeutics completes patient enrolment for phase I/II trial of cancer therapy ELC-100
Repare Therapeutics reports positive safety and tolerability data from Phase 1 MYTHIC trial